Standout Papers

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced ... 2017 2026 2020 2023 332
  1. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial (2017)
    Beatrice Seddon, Sandra J. Strauss et al. The Lancet Oncology
  2. Osteosarcoma (2022)
    Hannah C. Beird, Stefan Bielack et al. Nature Reviews Disease Primers

Immediate Impact

1 by Nobel laureates 4 from Science/Nature 56 standout
Sub-graph 1 of 21

Citing Papers

The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
Advances on immunotherapy for osteosarcoma
2024 Standout
7 intermediate papers

Works of Sandra J. Strauss being referenced

Osteosarcoma
2022 Standout
Incidence and survival of malignant bone sarcomas in England 1979–2007
2011
and 5 more

Author Peers

Author Last Decade Papers Cites
Sandra J. Strauss 1404 1230 562 802 91 2.9k
Heribert Juergens 1501 1078 471 1037 60 3.2k
Noah Federman 1290 1000 323 818 133 2.9k
Fariba Navid 1275 884 341 671 104 2.8k
Mrinal M. Gounder 1767 1805 621 1051 161 3.5k
Adrián Mariño‐Enríquez 2174 839 596 710 92 3.5k
Cynthia E. Herzog 1080 982 283 601 91 2.6k
Flavio Crippa 1082 1083 602 335 125 3.2k
Richard F. Riedel 1863 1165 295 678 108 3.3k
Federica Grosso 2969 1758 393 633 152 4.3k
Stefania Benini 1625 860 407 1377 89 3.1k

All Works

Loading papers...

Rankless by CCL
2026